Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA

Current Topics in Microbiology and Immunology

Volumn 311, Issue , 2006, Pages 155-178

  McCluskie, M J ^a   Krieg, A M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1018 ISS; ALUMINUM POTASSIUM SULFATE; B LYMPHOCYTE RECEPTOR; CPG 7909; CPG OLIGODEOXYNUCLEOTIDE; CYTRX; EMULSIGEN; FREUND ADJUVANT; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERFERON; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 12; KEYHOLE LIMPET HEMOCYANIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONTANIDE ISA 51; MONTANIDE ISA720; MYELOID DIFFERENTIATION FACTOR 88; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NORCROSS; PHOSPHORYL LIPID A; POLYMYXIN B; QS 21; QUILLL A; RECOMBINANT HEPATITIS B VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIXENSART; STRESS ACTIVATED PROTEIN KINASE; TITERMAX; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VAXIMMUNE; BACTERIAL DNA; LIGAND; OLIGODEOXYRIBONUCLEOTIDE; VIRUS DNA;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTIMICROBIAL ACTIVITY; APOPTOSIS; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DNA RECOMBINATION; DRUG CONJUGATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; HEPATITIS B; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; INTERNALIZATION; LEISHMANIASIS; MASS IMMUNIZATION; MONOTHERAPY; MUCOSAL IMMUNITY; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; REVIEW; SCHISTOSOMIASIS; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINATION; ACTIVE IMMUNIZATION; ANIMAL; BACTERIAL INFECTION; CPG ISLAND; GENETICS; IMMUNOLOGY; METABOLISM; SYNTHESIS; VIRUS INFECTION;

EUKARYOTA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; B-LYMPHOCYTES; BACTERIAL INFECTIONS; CPG ISLANDS; DNA, BACTERIAL; DNA, VIRAL; HUMANS; IMMUNITY, ACTIVE; LIGANDS; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9; VACCINES; VIRUS DISEASES;

EID: 33750961667     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/3-540-32636-7_6     Document Type: Review

References (142)

1. Pulendran B (2005) Variegation of the immune response with dendritic cells and pathogen recognition receptors. J Immunol 174:2457-2465
2. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745
3. Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD, Hood LE, Aderem A (2005) The evolution of vertebrate Toll-like receptors. Proc Natl Acad Sci U S A 102:9577-9582
4. Rankin R, Pontarollo R, Ioannou X, Krieg AM, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S (2001) CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Anti-sense Nucleic Acid Drug Dev 11:333-340
5. Hemmi H, Kaisho T, Takeda K, Akira S (2003) The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol 170:3059-3064
6. Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Payette P, Davis HL, Schetter C, Krieg AM (2004) Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology 113:212-223
7. Yasuda K, Yu P, Kirschning CJ, Schlatter B, Schmitz F, Heit A, Bauer S, Hochrein H, Wagner H (2005) Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J Immunol 174:6129-6136
8. Spies B, Hochrein H, Vabulas M, Huster K, Busch DH, Schmitz F, Heit A, Wagner H (2003) Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 171:5908-5912
9. Babiuk S, Mookherjee N, Pontarollo R, Griebel P, van Drunen Littel-van den Hurk S, Hecker R, Babiuk L (2004) TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunology 113:114-120
10. Tudor D, Dubuquoy C, Gaboriau V, Lefevre F, Charley B, Riffault S (2005) TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine 23:1258-1264
11. Ishii KJ, Suzuki K, Coban C, Takeshita F, Itoh Y, Matoba H, Kohn LD, Klinman DM (2001) Genomic DNA released by dying cells induces the maturation of APCs. J Immunol 167:2602-2607
12. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760
13. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987-995
14. Hayashi F, Means TK, Luster AD (2003) Toll-like receptors stimulate human neutrophil function. Blood 102:2660-2669
15. Li J, Ma Z, Tang ZL, Stevens T, Pitt B, Li S (2004) CpG DNA-mediated immune response in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 287:L552-L558
16. Platz J, Beisswenger C, Dalpke A, Koczulla R, Pinkenburg O, Vogelmeier C, Bals R (2004) Microbial DNA induces a host defense reaction of human respiratory epithelial cells. J Immunol 173:1219-1223
17. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549
18. Yi AK, Chang M, Peckham DW, Krieg AM, Ashman RF (1998) CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry [published erratum appears in J Immunol 1999 Jul 15;163(2):1093]. J Immunol 160:5898-5906
19. Hartmann G, Krieg AM (2000) Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 164:944-953
20. Brown WC, Estes DM, Chantler SE, Kegerreis KA, Suarez CE (1998) DNA and a CpG oligonucleotide derived from Babesia bovis aremitogenic for bovine B cells. Infect Immun 66:5423-5432
21. Ballas ZK, Rasmussen WL, Krieg AM (1996) Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157:1840-1845
22. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM (2000) Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164:1617-1624
23. Pisetsky DS, Reich CF 3rd (1998) The influence of base sequence on the immunological properties of defined oligonucleotides. Immunopharmacology 40:199-208
24. Roberts TL, Sweet MJ, Hume DA, Stacey KJ (2005) Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol 174:605-608
25. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G (2001) Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 31:2154-2163
26. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM (2004) Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34:251-262
27. Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N, Rothenfusser S, Endres S (2003) Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol 33:1633-1641
28. Marshall JD, Fearon K, Abbate C, Subramanian S, Yee P, Gregorio J, Coffman RL, Van Nest G (2003) Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol 73:781-792
29. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, Takaoka A, Taya C, Taniguchi T (2005) Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434:1035-1040
30. Krieg AM (1995) Uptake and localization of phosphodiester and chimeric oligodeoxynucleotides in normal and leukemic primary cells. In: Akhtar S (ed) Delivery strategies for antisense oligonucleotide therapeutics. CRC Press, Boca Raton, pp 177-190
31. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT (2004) TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5:190-198
32. Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, Bauer S (2004) Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 34:2541-2550
33. Yi AK, Tuetken R, Redford T, Waldschmidt M, Kirsch J, Krieg AM (1998) CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol 160:4755-4761
34. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H (2002) Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 32:1958-1968
35. Hacker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, Heeg K, Lipford GB, Wagner H (1998) CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J 17:6230-6240
36. Manzel L, Strekowski L, Ismail FM, Smith JC, Macfarlane DE (1999) Antagonism of immunostimulatory CpG-oligodeoxynucleotides by 4-aminoquinolines and other weak bases: mechanistic studies. J Pharmacol Exp Ther 291:1337-1347
37. Ishii KJ, Takeshita F, Gursel I, Gursel M, Conover J, Nussenzweig A, Klinman DM (2002) Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J Exp Med 196:269-274
38. Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H (2000) Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med 192:595-600
39. Schnare M, Holt AC, Takeda K, Akira S, Medzhitov R (2000) Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr Biol 10:1139-1142
40. Muzio M, Ni J, Feng P, Dixit VM (1997) IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278:1612-1615
41. Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A (1998) The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 187:2097-2101
42. Yi AK, Krieg AM (1998) Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol 161:4493-4497
43. Takeshita F, Klinman DM (2000) CpG ODN-mediated regulation of IL-12 p40 transcription. Eur J Immunol 30:1967-1976
44. Tsujimura H, Tamura T, Kong HJ, Nishiyama A, Ishii KJ, Klinman DM, Ozato K (2004) Toll-like receptor 9 signaling activates NF-kappaB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J Immunol 172:6820-6827
45. Choudhury BK, Wild JS, Alam R, Klinman DM, Boldogh I, Dharajiya N, Mileski WJ, Sur S (2002) In vivo role of p38 mitogen-activated protein kinase in mediating the anti-inflammatory effects of CpG oligodeoxynucleotide in murine asthma. J Immunol 169:5955-5961
46. Yi AK, Yoon JG, Krieg AM (2003) Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. Int Immunol 15:577-591
47. Yi AK, Yoon JG, Yeo SJ, Hong SC, English BK, Krieg AM (2002) Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J Immunol 168:4711-4720
48. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K, Matsuda M, Inoue J, Uematsu S, Takeuchi O, Akira S (2004) Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 5:1061-1068
49. Uematsu S, Sato S, Yamamoto M, Hirotani T, Kato H, Takeshita F, Matsuda M, Coban C, Ishii KJ, Kawai T, Takeuchi O, Akira S (2005) Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-alpha induction. J Exp Med 201:915-923
50. Yeo SJ, Yoon JG, Yi AK (2003) Myeloid differentiation factor 88-dependent post-transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: tumor necrosis factor-alpha receptor-associated factor 6, a diverging point in the Toll-like receptor 9-signaling. J Biol Chem 278:40590-40600
51. Yeo SJ, Gravis D, Yoon JG, Yi AK (2003) Myeloid differentiation factor 88-dependent transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: role of NF-kappaB and p38. J Biol Chem 278:22563-22573
52. Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O'Garra A, Vicari A, Trinchieri G (2005) Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med 201:1157-1167
53. Sun CM, Deriaud E, Leclerc C, Lo-Man R (2005) Upon TLR9 signaling, CD5+B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity 22:467-477
54. Duramad O, Fearon KL, Chan JH, Kanzler H, Marshall JD, Coffman RL, Barrat FJ (2003) IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. Blood 102:4487-4492
55. Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F, Reynard O, Taverne C, Merle P, Colombo MP, O'Garra A, Trinchieri G, Caux C (2002) Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 196:541-549
56. Cole AM, Ganz T, Liese AM, Burdick MD, Liu L, Strieter RM (2001) Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity. J Immunol 167:623-627
57. Salazar-Mather TP, Hamilton TA, Biron CA (2000) A chemokine-to-cytokine- tochemokine cascade critical in antiviral defense. J Clin Invest 105:985-993
58. Liu MT, Chen BP, Oertel P, Buchmeier MJ, Armstrong D, Hamilton TA, Lane TE (2000) The T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease. J Immunol 165:2327-2330
59. Mahalingam S, Farber JM, Karupiah G (1999) The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity In vivo. J Virol 73:1479-1491
60. Tannenbaum CS, Tubbs R, Armstrong D, Finke JH, Bukowski RM, Hamilton TA (1998) The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J Immunol 161:927-932
61. Narvaiza I, Mazzolini G, Barajas M, Duarte M, Zaratiegui M, Qian C, Melero I, Prieto J (2000) Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol 164:3112-3122
62. Pertl U, Luster AD, Varki NM, Homann D, Gaedicke G, Reisfeld RA, Lode HN (2001) IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J Immunol 166:6944-6951
63. Weighardt H, Feterowski C, Veit M, Rump M, Wagner H, Holzmann B (2000) Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J Immunol 165:4537-4543
64. Utaisincharoen P, Kespichayawattana W, Anuntagool N, Chaisuriya P, Pichyangkul S, Krieg AM, Sirisinha S (2003) CpG ODN enhances uptake of bacteria by mouse macrophages. Clin Exp Immunol 132:70-75
65. Klinman DM, Currie D, Gursel I, Verthelyi D (2004) Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert Opin Biol Ther 4:937-946
66. Kemp TJ, Elzey BD, Griffith TS (2003) Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol 171:212-218
67. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416:603-607
68. Liu YJ (2005) IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23:275-306
69. Pulendran B (2004) Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 199:227-250
70. Moseman EA, Liang XQ, Dawson AJ, Panoskaltsis-Mortari A, Krieg AM, Liu YJ, Blazar BR, Chen W (2004) Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 173:4433-4442
71. Rothenfusser S, Tuma E, Endres S, Hartmann G (2002) Plasmacytoid dendritic cells: the key to CpG. Hum Immunol 63:1111-1119
72. Rothenfusser S, Hornung V, Ayyoub M, Britsch S, Towarowski A, Krug A, Sarris A, Lubenow N, Speiser D, Endres S, Hartmann G (2004) CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood 103:2162-2169
73. Sparwasser T, Vabulas RM, Villmow B, Lipford GB, Wagner H (2000) Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol 30:3591-3597
74. Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM (1998) CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen [published erratum appears in J Immunol 1999 Mar 1;162(5):3103]. J Immunol 160:870-876
75. He B, Qiao X, Cerutti A (2004) CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 173:4479-4491
76. Lipford GB, Sparwasser T, Zimmermann S, Heeg K, Wagner H (2000) CpG-DNA mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol 165:1228-1235
77. Chu RS, McCool T, Greenspan NS, Schreiber JR, Harding CV (2000) CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Infect Immun 68:1450-1456
78. Kovarik J, Bozzotti P, Tougne C, Davis HL, Lambert PH, Krieg AM, Siegrist CA (2001) Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens. Immunology 102:67-76
79. von Hunolstein C, Teloni R, Mariotti S, Recchia S, Orefici G, Nisini R (2000) Synthetic oligodeoxynucleotide containing CpG motif induces an anti-polysaccharide type 1-like immune response after immunization of mice with Haemophilus influenzae type b conjugate vaccine. Int Immunol 12:295-303
80. Tighe H, Takabayashi K, Schwartz D, Marsden R, Beck L, Corbeil J, Richman DD, Eiden JJ Jr, Spiegelberg HL, Raz E (2000) Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 30:1939-1947
81. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B, Giese T, Gires O, Endres S, Hartmann G (2003) Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63:6478-6487
82. Kim SK, Ragupathi G, Musselli C, Choi SJ, Park YS, Livingston PO (2000) Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine 18:597-603
83. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV (1997) CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186:1623-1631
84. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K (1997) CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol 27:2340-2344
85. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E (1997) Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants [see comments]. Nat Med 3:849-854
86. Zwaveling S, Mota SCF, Nouta J, Johnson M, Lipford GB, Offringa R, van der Burg SH, Melief CJM (2002) Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169:350-358
87. Davis HL (2000) Use of CpG DNA for enhancing specific immune responses. Curr Top Microbiol Immunol 247:171-183
88. Kim SK, Ragupathi G, Cappello S, Kagan E, Livingston PO (2001) Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine 19:530-537
89. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM (1989) Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 169:59-72
90. Sher A (1992) Schistosomiasis. Parasitizing the cytokine system. Nature 356:565-566
91. Chisari FV, Ferrari C (1995) Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13:29-60
92. World Health Organization (2001) Global Alliance for Vaccines and Immunization (GAVI). Fact Sheet No. 169
93. Freidag BL, Melton GB, Collins F, Klinman DM, Cheever A, Stobie L, Suen W, Seder RA (2000) CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect Immun 68:2948-2953
94. Jones TR, Obaldia N 3rd, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, Davis HL, Krieg AM, Hoffman SL (1999) Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 17:3065-3071
95. Walker PS, Scharton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, Udey MC, Vogel JC (1999) Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-γ-dependent mechanisms. Proc Natl Acad Sci U S A 96:6970-6975
96. Eastcott JW, Holmberg CJ, Dewhirst FE, Esch TR, Smith DJ, Taubman MA (2001) Oligonucleotide containing CpG motifs enhances immune response tomucosally or systemically administered tetanus toxoid. Vaccine 19:1636-1642
97. Leelawongtawon R, Somroop S, Chaisri U, Tongtawe P, Chongsa-nguan M, Kalambaheti T, Tapchaisri P, Pichyangkul S, Sakolvaree Y, Kurazono H, Hayashi H, Chaicumpa W (2003) CpG DNA, liposome and refined antigen oral cholera vaccine. Asian Pac J Allergy Immunol 21:231-239
98. Nesburn AB, Ramos TV, Zhu X, Asgarzadeh H, Nguyen V, BenMohamed L (2005) Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine 23:873-883
99. Hogarth PJ, Jahans KJ, Hecker R, Hewinson RG, Chambers MA (2003) Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs. Vaccine 21:977-982
100. Vleugels B, Ververken C, Goddeeris BM (2002) Stimulatory effect of CpG sequences on humoral response in chickens. Poult Sci 81:1317-1321
101. Alcon VL, Foldvari M, Snider M, Willson P, Gomis S, Hecker R, Babiuk LA, Baca-Estrada ME (2003) Induction of protective immunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in a lipid-based delivery system (Biphasix). Vaccine 21:1811-1814
102. Kringel H, Dubey JP, Beshah E, Hecker R, Urban JF Jr (2004) CpG-oligodeoxynucleotides enhance porcine immunity to Toxoplasma gondii. Vet Parasitol 123:55-66
103. Rankin R, Pontarollo R, Gomis S, Karvonen B, Willson P, Loehr BI, Godson DL, Babiuk LA, Hecker R, van Drunen Littel-van den Hurk S (2002) CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D. Vaccine 20:3014-3022
104. Wedlock DN, Denis M, Skinner MA, Koach J, de Lisle GW, Vordermeier HM, Hewinson RG, van Drunen Littel-van den Hurk S, Babiuk LA, Hecker R, Buddle BM (2005) Vaccination of cattle with Mycobacterium bovis culture filtrate proteins and CpG oligodeoxynucleotides induces protection against bovine tuberculosis. Vet Immunol Immunopathol 106:53-63
105. Ioannou XP, Gomis SM, Karvonen B, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S (2002) CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21:127-137
106. Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, Eravani D, Sanos S, Kaye P, Taghikhani M, Jamshidi S, Rad MA (2005) Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23:3716-3725
107. Davis HL, Suparto II, Weeratna RR, Jumintarto, Iskandriati DD, Chamzah SS, Ma'ruf AA, Nente CC, Pawitri DD, Krieg AM, Heriyanto, Smits W, Sajuthi DD (2000) CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18:1920-1924
108. Kumar S, Jones TR, Oakley MS, Zheng H, Kuppusamy SP, Taye A, Krieg AM, Stowers AW, Kaslow DC, Hoffman SL (2004) CpG oligodeoxynucleotide and montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun 72:949-957
109. Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg AM, Cameron DW (2005) CPG 7909 adjuvant improves hepatitis B virus vaccine sero-protection in antiretroviral-treated HIV-infected adults. AIDS 19:1473-1479
110. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J (2004) CpG 7909, animmunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24:693-702
111. Cooper CL, Davis HL, Morris ML, et al (2004) Safety and immunogenicity of CpG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22:3136-3143
112. Halperin SA, Van Nest G, Smith B, Abtahi S, Whiley H, Eiden JJ (2003) A phase I study of the safety andimmunogenicity of recombinan the patitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21:2461-2467
113. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P (2005) Rapid and strong human CD8(+) T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115:739-746
114. Weeratna RD, McCluskie MJ, Xu Y, Davis HL (2000) CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 18:1755-1762
115. Sugai T, Mori M, Nakazawa M, Ichino M, Naruto T, Kobayashi N, Kobayashi Y, Minami M, Yokota S (2005) A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine. Vaccine 23:5450-5456
116. Oumouna M, Mapletoft JW, Karvonen BC, Babiuk LA, van Drunen Littel-van den Hurk S (2005) Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine. J Virol 79:2024-2032
117. Hancock GE, Heers KM, Pryharski KS, Smith JD, Tiberio L (2003) Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus. Vaccine 21:4348-4358
118. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL (1998) CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA 95:15553-15558
119. Weeratna RD, Brazolot Millan CL, McCluskie MJ, Siegrist CA, Davis HL (2001) Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. FEMS Immunol Med Microbiol 30:241-247
120. Schirmbeck R, Reimann J (2001) Modulation of gene-gun-mediated Th2 immunity to hepatitis B surface antigen by bacterial CpG motifs or IL-12. Intervirology 44:115-123
121. Zhou X, Zheng L, Liu L, Xiang L, Yuan Z (2003) T helper 2 immunity to hepatitis B surface antigen primed by gene-gun-mediated DNA vaccination can be shifted towards T helper 1 immunity by codelivery of CpG motif-containing oligodeoxynucleotides. Scand J Immunol 58:350-357
122. Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL (2001) CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol 32:65-71
123. Manning BM, Enioutina EY, Visic DM, Knudson AD, Daynes RA (2001) CpG DNA functions as an effective adjuvant for the induction of immune responses in aged mice. Exp Gerontol 37:107-126
124. Maletto B, Ropolo A, Moron V, Pistoresi-Palencia MC (2002) CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice. J Leukoc Biol 72:447-454
125. Alignani D, Maletto B, Liscovsky M, Ropolo A, Moron G, Pistoresi-Palencia MC (2005) Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice. J Leukoc Biol 77:898-905
126. Weeratna R, Comanita L, Davis HL (2003) CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. Immunol Cell Biol 81:59-62
127. Siegrist CA, Pihlgren M, Tougne C, Efler SM, Morris ML, AlAdhami MJ, Cameron DW, Cooper CL, Heathcote J, Davis HL, Lambert PH (2004) Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 23:615-622
128. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H (1992) The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10:75-88
129. Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM (1998) CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16:1216-1224
130. Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL (2001) Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 166:3451-3457
131. McCluskie MJ, Davis HL (1998) CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 161:4463-4466
132. McCluskie MJ, Davis HL (2001) Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19:413-422
133. Kwant A, Rosenthal KL (2004) Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 22:3098-3104
134. McCluskie MJ, Weeratna RD, Krieg AM, Davis HL (2001) CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19:950-957
135. Dong JL, Liang BG, Jin YS, Zhang WJ, Wang T (2005) Oral immunization with pBsVP6-transgenic alfalfa protects mice against rotavirus infection. Virology 339:153-163
136. Dumais N, Patrick A, Moss RB, Davis HL, Rosenthal KL (2002) Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J Infect Dis 186:1098-1105
137. Berry LJ, Hickey DK, Skelding KA, Bao S, Rendina AM, Hansbro PM, Gockel CM, Beagley KW (2004) Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun 72:1019-1028
138. Joseph A, Louria-Hayon I, Plis-Finarov A, Zeira E, Zakay-Rones Z, Raz E, Hayashi T, Takabayashi K, Barenholz Y, Kedar E (2002) Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 20:3342-3354
139. McCluskie MJ, Weeratna RD, Davis HL (2000) Intranasal immunization of mice with CpG DNA induces strong systemic andmucosal responses that are influenced by other mucosal adjuvants and antigen distribution. Mol Med 6:867-877
140. Jiang W, Baker HJ, Smith BF (2003) Mucosal immunization with helicobacter, CpG DNA, and cholera toxin is protective. Infect Immun 71:40-46
141. McCluskie MJ, Weeratna RD, Clements JD, Davis HL (2001) Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants. Vaccine 19:3759-3768
142. Olszewska W, Partidos CD, Steward MW (2000) Antipeptide antibody responses following intranasal immunization: effectiveness of mucosal adjuvants. Infect Immun 68:4923-4929